Thank you for visiting this site to learn more about our clinical research trials of niraparib for women with ovarian, fallopian tube or primary peritoneal cancer. TESARO’s goal is to use the information we gather from these trials to develop a new treatment that may benefit many women who have been diagnosed with these diseases.
Participating in a clinical trial is a selfless decision that has the potential to positively impact thousands of lives. The clinical trials described on this site will advance our understanding of niraparib and how ovarian, fallopian tube and primary peritoneal cancer responds to different treatments. By joining a trial, you may also help other women who may be diagnosed with these cancers in the future.
All of us at TESARO are dedicated to improving the lives of people with cancer by developing safer and more effective medicines. We thank you for taking the time to thoughtfully consider participation in our clinical trials as an option for your future care.
For more information about TESARO, please visit www.tesarobio.com.
Chief Executive Officer, TESARO
Mary Lynne Hedley, Ph.D.
President & Chief Operating Officer, TESARO